Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Quarterly Statistics, Q3 2016

Executive Summary

A review of biopharma start-up dealmaking and financing from July through September 2016, based on data from Strategic Transactions.

You may also be interested in...



IPO Update: Novan, AC Immune End Summer Slowdown As Market Improves

Novan and AC Immune ended September with the first biopharma IPOs in 40 days as the performance of newly public companies’ stocks head into an upswing.

Boehringer Gets Option To Buy ViraTherapeutics And Cancer Virus Therapy

The German pharma agreed to pay up to €210m to investigate ViraTherapeutics' lead candidate, VSV-GP, alone and in combination, with an option to buy ViraTherapeutics depending on the outcome of Phase I studies.

Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn

Allergan will pay a huge premium – up to $1.7bn in a milestone-heavy deal – for Tobira and $50m up front for the preclinical startup Akarna to expand its gastrointestinal franchise into the potentially lucrative NASH market.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097458

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel